

**Pharmacist Assessment Record (PAR) – Therapeutic Substitution in Extraordinary Circumstances**

|  |  |
| --- | --- |
| Patient Name: Click or tap here to enter text. | Prescription Date: Click or tap to enter a date. |
| Patient Address: Click or tap here to enter text. | **Patient Phone Number** (Optional)**:**Click or tap here to enter text. |
| Original Prescription | **Therapeutic Substitution** |
| Drug Name/Strength/Dosage:Click or tap here to enter text.Quantity Prescribed:Click or tap here to enter text.Direction for Use:Click or tap here to enter text. | **Drug Name/Strength/Dosage:**Click or tap here to enter text.**Quantity Prescribed:**Click or tap here to enter text.**Direction for Use:**Click or tap here to enter text. |
| Patient’s Consent Received: [ ]  in writing [ ]  verbally |
| Rationale for Prescribing the Therapeutic Substitution (check all that apply):[ ]  Patient’s medication history has been assessed and indicates a chronic stabilized use of the drug [ ]  Patient is at immediate risk of interruption of therapy in response to the extenuating circumstances (e.g., drug recall, drug shortage, prescriber not available, problem with administration). [ ]  Prescribed at the request of and/or in consultation with the patient [ ]  Other factors considered (e.g., clinical, financial needs of patient): Click or tap here to enter text. |
| Other Relevant Patient Information (e.g., drug-related problems, actions plans, patient counselling provided):[ ]  Patient’s PIP profile reviewed (current and previous medications)[ ]  Patient’s eHR reviewed Relevant labs: Click or tap here to enter text.[ ]  Patient’s Diagnosis: Click or tap here to enter text.Diagnosis indicated on official drug monograph:[ ]  Yes Continue.[ ]  No Refer to primary practitioner. Pharmacists are not permitted to prescribe for off-label use.[ ]  Goals of Therapy: Click or tap here to enter text. |
| Monitoring and Follow Up Plan: Click or tap here to enter text.Pharmacist Follows up with Patient: Click or tap here to enter text.Pharmacist to follow up with patient to ensure safe and effective use of medication in:[ ]  The next 72 hours [ ]  The next 7 days [ ]  Other (best practice time frames specific to the drug): Click or tap here to enter text.Follow up completed on Click or tap to enter a date.. Details of follow-up: Click or tap here to enter text.(Report any suspected adverse drug reaction or side-effect to [MedEffect Canada](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html))Referral to Primary Care Provider: Click or tap here to enter text.Patient instructed to call primary care provider’s office to make an appointment to review their drug therapy within: [ ]  The next 72 hours [ ]  The next 7 days [ ]  Other (specify details): Click or tap here to enter text. |
| Name of prescribing pharmacist: Click or tap here to enter text.Pharmacy contact information: Click or tap here to enter text. |
| Primary care provider notified: [ ]  Yes (always required for Therapeutic Substitution PARs)Name: Click or tap here to enter text. Fax #: Click or tap here to enter text. |
| Required Procedures Before Making a Therapeutic Substitution:Unless previously confirmed, prior to prescribing a therapeutic substitution, the pharmacist must make reasonable efforts to:[ ]  Find stock for the patient’s current prescribed drug from other local pharmacies;[ ]  Exhaust all options to procure stock from authorized distributors; and[ ]  Contact the patient’s primary practitioner to collaborate on an alternative where possible. |
| For SCPP auditing purposes:Emergency provisions used, as declared by the SCPP (check all that apply):[ ]  Therapeutic Substitution in Extraordinary Circumstance (Part K, section 10(5)(e))[ ]  Back-to-Back pharmacist prescribing (Part K, section 10(5)(b)) 🡪 Not permitted for TS unless otherwise directed by the RegistrarEmergency Provisions not permitted for TS:Prescribe quantities that exceed limits in the bylaws (Part K Section 10(5)(a))Prescribe when an active patient-practitioner relationship no longer exists (Part K Section 10(5)(c)) Drug substituted shares the following scientific property with original drug (see [WHO ATC Classification](https://www.whocc.no/atc/structure_and_principles/#Structure)): [ ]  Chemical Structure[ ]  Mechanism of Action[ ]  Therapeutic or Physiologic Effect 🡪 Not permitted for TS outside of a CPA |

 *Note: This document fulfills the requirements of the Saskatchewan College of Pharmacy Professionals Regulatory Bylaws Part K Section 2(2) and select sections of the* [*SCPP Therapeutic Substitution in Extraordinary Circumstances Policy*](https://saskpharm.ca/document/7367/REF_Therapeutic_Substitutions_in_Extraordinary_Circumstances.pdf)*.*

**RELATED RESOURCES**

1. [Therapeutic Substitution in Extraordinary Circumstances Policy](https://saskpharm.ca/document/7367/REF_Therapeutic_Substitutions_in_Extraordinary_Circumstances.pdf)
2. [Prescriptive Authority Decision Making Framework](https://saskpharm.ca/document/6107/REF_Prescriptive_Authority_Decision_Making_Framework.pdf)
3. [Prescriptive Authority - Pharmacist](https://saskpharm.ca/document/6106/REF_Prescriptive_Authority_Pharmacist.pdf)
4. [Emergency Exemptions for Prescribing Authority](https://scp.in1touch.org/document/5442/REF_Prescribing_Authority_Exemptions.pdf)
5. [Summary of Record Keeping Requirements](https://saskpharm.ca/document/5233/REF_Record_Keeping_Requirements_20190919.pdf) to distinguish between PAR as a ‘prescription’ and PAR as a ‘patient record’